T
Tingfei Hu
Researcher at Cleveland Clinic
Publications - 22
Citations - 2632
Tingfei Hu is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Myocardial infarction & Bivalirudin. The author has an hindex of 16, co-authored 20 publications receiving 2500 citations.
Papers
More filters
Journal ArticleDOI
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
Deepak L. Bhatt,Marcus Flather,Werner Hacke,Peter B. Berger,Henry R. Black,William E. Boden,Patrice Cacoub,Eric A. Cohen,Mark A. Creager,J. Donald Easton,Christian W. Hamm,Graeme J. Hankey,S. Claiborne Johnston,Koon-Hou Mak,Jean-Louis Mas,Gilles Montalescot,Thomas A. Pearson,P. Gabriel Steg,Steven R. Steinhubl,Michael A. Weber,Liz Fabry-Ribaudo,Tingfei Hu,Eric J. Topol,Keith A.A. Fox,Charisma Investigators +24 more
TL;DR: In this analysis of the CHARISMA trial, the large number of patients with documented prior MI, ischemic stroke, or symptomatic PAD appeared to derive significant benefit from dual antiplatelet therapy with clopidogrel plus aspirin.
Journal ArticleDOI
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Stephen J. Nicholls,E. Murat Tuzcu,Ilke Sipahi,Adam W. Grasso,Paul Schoenhagen,Tingfei Hu,Kathy Wolski,Tim Crowe,Milind Y. Desai,Stanley L. Hazen,Samir R. Kapadia,Steven E. Nissen +11 more
TL;DR: The findings suggest that statin benefits are derived from both reductions in atherogenic lipoprotein levels and increases in HDL-C, although it remains to be determined whether the atherosclerotic regression associated with these changes in lipid levels will translate to meaningful reductions in clinical events and improved clinical outcomes.
Journal ArticleDOI
Cardiac implantable electronic device infections: presentation, management, and patient outcomes.
Khaldoun G. Tarakji,Eric J. Chan,Daniel J. Cantillon,Aaron L. Doonan,Tingfei Hu,Steven K. Schmitt,Thomas G. Fraser,Alice Kim,Steven M. Gordon,Bruce L. Wilkoff +9 more
TL;DR: In this paper, a total of 412 patients (age 68 15 years) were included in the study, and the majority of patients (241 patients) presented with localized infection involving the device pocket.
Journal ArticleDOI
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
John W. Eikelboom,Graeme J. Hankey,J. Thom,Deepak L. Bhatt,P. Gabriel Steg,Gilles Montalescot,S. Claiborne Johnston,Steven R. Steinhubl,Koon Hou Mak,J. Donald Easton,Christian W. Hamm,Tingfei Hu,Keith A.A. Fox,Eric J. Topol +13 more
TL;DR: In aspirin-treated patients, urinary concentrations of 11-dehydro thromboxane B2 are an externally valid and potentially modifiable determinant of stroke, myocardial infarction, or cardiovascular death in patients at risk for atherothrombotic events.
Journal ArticleDOI
The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.
Jacqueline Saw,Deepak L. Bhatt,David J. Moliterno,Sorin J. Brener,Steven R. Steinhubl,A. Michael Lincoff,James E. Tcheng,Robert A. Harrington,Maarten L. Simoons,Tingfei Hu,Mobeen A. Sheikh,Dean J. Kereiakes,Eric J. Topol +12 more
TL;DR: The presence of PAD is associated with higher rates of post-PCI death and MI, and is an independent predictor of short- and long-term mortality.